Current Fungal Infection Reports

, Volume 4, Issue 2, pp 87–95 | Cite as

Use of Antifungal Combination Therapy: Agents, Order, and Timing

  • Melissa D. JohnsonEmail author
  • John R. Perfect


Given the substantial morbidity and mortality related to invasive fungal infections, treatment with a combination of antifungal agents is often considered. A growing body of literature from in vitro studies, animal models, and clinical experience provides data evaluating this approach. This review describes combination antifungal strategies for the management of cryptococcal meningitis, invasive candidiasis, invasive aspergillosis, and rare mold infections. The potential effects that sequencing and timing have on the efficacy of such approaches are discussed, with a focus on recent clinical data in this arena.


Antifungal agents Mycoses Drug therapy, combination Candidiasis Amphotericin B Flucytosine Hematopoietic stem cell transplantation Aspergillosis Triazoles Flucytosine Imidazoles Fluconazole Zygomycosis Mucormycosis Fungi Echinocandins Aspergillus Meningitis, cryptococcal Cryptococcosis Cryptococcus Candida 



Dr. Johnson is a consultant for Enzon Pharmaceuticals and has received research grants from Merck, Pfizer, and Basilea Pharmaceutica. Dr. Perfect is a speaker and Principal Investigator for Astellas, Enzon, Merck, Pfizer, and Schering-Plough.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lewis RE: Decision making in antifungal monotherapy versus combination therapy. Pharmacotherapy 2006, 26:61 S–67 S.CrossRefPubMedGoogle Scholar
  2. 2.
    Lewis RE, Kontoyiannis DP: Rationale for combination antifungal therapy. Pharmacotherapy 2001, 21:149 S–164 S.CrossRefPubMedGoogle Scholar
  3. 3.
    Kontoyiannis DP, Lewis RE: Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004, 126:165–175.CrossRefPubMedGoogle Scholar
  4. 4.
    Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al.: Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693–715.CrossRefPubMedGoogle Scholar
  5. 5.
    Powers JH: Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis 2004, 39(Suppl 4):S228–S235.CrossRefPubMedGoogle Scholar
  6. 6.
    Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH: Amphotericin B: time for a new “gold standard.” Clin Infect Dis 2003, 37:415–425.CrossRefPubMedGoogle Scholar
  7. 7.
    Ellis D: Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002, 49(Suppl 1):7–10.PubMedGoogle Scholar
  8. 8.
    Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327–360.CrossRefPubMedGoogle Scholar
  9. 9.
    • Fera MT, La Camera E, De Sarro A: New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 2009, 7:981–998. This paper describes newer azole and echinocandin antifungal agents with respect to pharmacology and microbiologic activity CrossRefPubMedGoogle Scholar
  10. 10.
    Manavathu EK, Alangaden GJ, Chandrasekar PH: Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003, 51:1423–1425.CrossRefPubMedGoogle Scholar
  11. 11.
    Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408–415.CrossRefPubMedGoogle Scholar
  12. 12.
    Arikan S, Sancak B, Alp S, et al.: Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008, 46:567–573.CrossRefPubMedGoogle Scholar
  13. 13.
    Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al.: Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006, 50:917–921.CrossRefPubMedGoogle Scholar
  14. 14.
    • Gonzalez GM: In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009, 47:71–76. This in vitro study compared the microbiologic activity of newer azoles for rare molds and dimorphic fungi CrossRefPubMedGoogle Scholar
  15. 15.
    Fisher BT, Chiller TM, Prasad PA, et al.: Hospitalizations for coccidioidomycosis at forty-one children’s hospitals in the United States. Pediatr Infect Dis J 2010, 29:243–247.CrossRefPubMedGoogle Scholar
  16. 16.
    Wheat LJ, Freifeld AG, Kleiman MB, et al.: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807–825.CrossRefPubMedGoogle Scholar
  17. 17.
    Kauffman CA, Bustamante B, Chapman SW, Pappas PG: Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:1255–1265.CrossRefPubMedGoogle Scholar
  18. 18.
    Chapman SW, Dismukes WE, Proia LA, et al.: Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:1801–1812.CrossRefPubMedGoogle Scholar
  19. 19.
    Galgiani JN, Ampel NM, Blair JE, et al.: Coccidioidomycosis. Clin Infect Dis 2005, 41:1217–1223.CrossRefPubMedGoogle Scholar
  20. 20.
    Freifeld A, Proia L, Andes D, et al.: Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009, 53:1648–1651.CrossRefPubMedGoogle Scholar
  21. 21.
    Catanzaro A, Cloud GA, Stevens DA, et al.: Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007, 45:562–568.CrossRefPubMedGoogle Scholar
  22. 22.
    Kirkpatrick WR, Coco BJ, Patterson TF: Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2006, 50:1567–1569.CrossRefPubMedGoogle Scholar
  23. 23.
    Ernst EJ, Klepser ME, Pfaller MA: In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time. Diagn Microbiol Infect Dis 1998, 32:205–210.CrossRefPubMedGoogle Scholar
  24. 24.
    Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221–1228.CrossRefPubMedGoogle Scholar
  25. 25.
    Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004, 363:1764–1767.CrossRefPubMedGoogle Scholar
  26. 26.
    • Pappas PG, Chetchotisakd P, Larsen RA, et al.: A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009, 48:1775–1783. This open-label phase 2 trial compared the combination of amphotericin B and fluconazole (at high or low dosages) versus amphotericin B alone as induction therapy for HIV-associated cryptococcal meningitis.CrossRefPubMedGoogle Scholar
  27. 27.
    •• Chaux GE: Combination antifungal therapy for invasive mold infections involving polyenes: a case report and brief review of the literature. Inf Dis Clin Pract 2010, 18:7–15. This review summarizes cases in which lipid formulations of amphotericin B were used in combination with other antifungals for the management of invasive mold infections.CrossRefGoogle Scholar
  28. 28.
    Patterson TF, Boucher HW, Herbrecht R, et al.: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005, 41:1448–1452.CrossRefPubMedGoogle Scholar
  29. 29.
    •• Cornely OA, Maertens J, Bresnik M, et al.: Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B. J Antimicrob Chemother 2010, 65:114–117. This analysis suggested that prior azole prophylactic therapy or early empiric therapy did not affect overall response or mortality among patients who received LAmB therapy for invasive filamentous fungal infection CrossRefPubMedGoogle Scholar
  30. 30.
    Canton E, Peman J, Gobernado M, et al.: Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 2005, 49:1593–1596.CrossRefPubMedGoogle Scholar
  31. 31.
    Gil-Lamaignere C, Muller FM: Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr. Int J Antimicrob Agents 2004, 23:520–523.CrossRefPubMedGoogle Scholar
  32. 32.
    Garcia-Effron G, Gomez-Lopez A, Mellado E, et al.: In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 2004, 53:1086–1089.CrossRefPubMedGoogle Scholar
  33. 33.
    Mosquera J, Sharp A, Moore CB, et al.: In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002, 50:189–194.CrossRefPubMedGoogle Scholar
  34. 34.
    Kirkpatrick WR, Vallor AC, McAtee RK, et al.: Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. Antimicrob Agents Chemother 2005, 49:4751–4753.CrossRefPubMedGoogle Scholar
  35. 35.
    Ghannoum MA, Elewski B: Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol 1999, 6:921–923.PubMedGoogle Scholar
  36. 36.
    Rothe A, Seibold M, Hoppe T, et al.: Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004, 83:394–397.CrossRefPubMedGoogle Scholar
  37. 37.
    Li JY, Yong TY, Grove DI, Coates PT: Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis 2008, 10:63–65.CrossRefPubMedGoogle Scholar
  38. 38.
    Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ: Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007, 39:87–90.CrossRefPubMedGoogle Scholar
  39. 39.
    Gosbell IB, Toumasatos V, Yong J, et al.: Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003, 46:233–236.CrossRefPubMedGoogle Scholar
  40. 40.
    Kesson AM, Bellemore MC, O’Mara TJ, et al.: Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009, 48:1257–1261.CrossRefPubMedGoogle Scholar
  41. 41.
    Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother 2009, 43:1647–1657.CrossRefPubMedGoogle Scholar
  42. 42.
    Tunger O, Bayram H, Degerli K, et al.: Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis. Saudi Med J 2008, 29:728–733.PubMedGoogle Scholar
  43. 43.
    Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564–2568.CrossRefPubMedGoogle Scholar
  44. 44.
    MacCallum DM, Whyte JA, Odds FC: Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005, 49:3697–3701.CrossRefPubMedGoogle Scholar
  45. 45.
    Petraitis V, Petraitiene R, Hope WW, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009, 53:2382–2391.CrossRefPubMedGoogle Scholar
  46. 46.
    Ibrahim AS, Gebremariam T, Fu Y, et al.: Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008, 52:1556–1558.CrossRefPubMedGoogle Scholar
  47. 47.
    • Rieger CT, Ostermann H, Kolb HJ, et al.: A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Ann Hematol 2008, 87:915–922. This small, retrospective study of combination antifungal therapy for the treatment of invasive fungal infections in patients with hematologic malignancies suggested that combination therapy was feasible in this population CrossRefPubMedGoogle Scholar
  48. 48.
    Bland CM, Thomas S: Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans. Ann Pharmacother 2009, 43:528–531.CrossRefPubMedGoogle Scholar
  49. 49.
    Nivoix Y, Zamfir A, Lutun P, et al.: Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006, 52:67–74.CrossRefPubMedGoogle Scholar
  50. 50.
    Singh N, Limaye AP, Forrest G, et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320–326.CrossRefPubMedGoogle Scholar
  51. 51.
    Marr KA, Boeckh M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797–802.CrossRefPubMedGoogle Scholar
  52. 52.
    Denning DW, Marr KA, Lau WM, et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53:337–349.CrossRefPubMedGoogle Scholar
  53. 53.
    • Kontoyiannis DP, Ratanatharathorn V, Young JA, et al.: Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009, 11:89–93. This study describes multicenter experience with micafungin in managing invasive aspergillosis in hematopoietic stem cell transplant recipients. Most patients received combination antifungal therapy for infections that were refractory to initial therapy.CrossRefPubMedGoogle Scholar
  54. 54.
    • Thomas A, Korb V, Guillemain R, et al.: Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J Clin Pharm Therapeut 2010, 35:49–53. This small, retrospective study reported efficacy of voriconazole plus caspofungin for management of invasive aspergillosis in lung transplant recipients CrossRefGoogle Scholar
  55. 55.
    Maertens J, Glasmacher A, Herbrecht R, et al.: Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006, 107:2888–2897.CrossRefPubMedGoogle Scholar
  56. 56.
    Reed C, Bryant R, Ibrahim AS, et al.: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364–371.CrossRefPubMedGoogle Scholar
  57. 57.
    Reed C, Ibrahim A, Edwards JE Jr, et al.: Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968–3969.CrossRefPubMedGoogle Scholar
  58. 58.
    Perfect JR, Dismukes WE, Dromer F, et al.: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291–322.CrossRefPubMedGoogle Scholar
  59. 59.
    • Nussbaum JC, Jackson A, Namarika D, et al.: Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010, 50:338–344. This randomized, prospective clinical trial established efficacy of oral fluconazole plus flucytosine compared with high-dose fluconazole monotherapy for induction therapy of HIV-associated cryptococcal meningitis.CrossRefPubMedGoogle Scholar
  60. 60.
    Natarajan G, Lulic-Botica M, Rongkavilit C, et al.: Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005, 25:770–777.CrossRefPubMedGoogle Scholar
  61. 61.
    Wertz KK, Pretzlaff RK: Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med 2004, 5:181–183.CrossRefPubMedGoogle Scholar
  62. 62.
    Pappas PG, Kauffman CA, Andes D, et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503–535.CrossRefPubMedGoogle Scholar
  63. 63.
    Falcone M, Barzaghi N, Carosi G, et al.: Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 2009, 88:160–168.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Campbell University College of Pharmacy & Health SciencesDurhamUSA
  2. 2.Division of Infectious Diseases & International HealthDuke University Medical CenterDurhamUSA

Personalised recommendations